{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T19:20:50Z","timestamp":1757618450819,"version":"3.44.0"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,6,26]],"date-time":"2025-06-26T00:00:00Z","timestamp":1750896000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,6,26]],"date-time":"2025-06-26T00:00:00Z","timestamp":1750896000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"VZ FNM","award":["00064203\/6001"],"award-info":[{"award-number":["00064203\/6001"]}]},{"name":"GAUK","award":["227023"],"award-info":[{"award-number":["227023"]}]},{"DOI":"10.13039\/100007397","name":"Charles University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100007397","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Drugs"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1007\/s40272-025-00702-9","type":"journal-article","created":{"date-parts":[[2025,6,26]],"date-time":"2025-06-26T12:35:43Z","timestamp":1750941343000},"page":"629-640","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Association of Serum Levels of Ustekinumab, Vedolizumab, and Faecal Calprotectin in Paediatric Patients with Inflammatory Bowel Diseases: A Prospective Observational Study"],"prefix":"10.1007","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2641-7280","authenticated-orcid":false,"given":"J.","family":"Bronsky","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Zarubova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Copova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Durilova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Kazeka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Kubat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Lerchova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Mitrova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Vlckova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Duskova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Dostalikova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"O.","family":"Hradsky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,6,26]]},"reference":[{"issue":"2","key":"702_CR1","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1097\/MPG.0000000000002035","volume":"67","author":"D Turner","year":"2018","unstructured":"Turner D, et al. Management of paediatric ulcerative colitis, part 1: ambulatory care-an evidence-based guideline from European Crohn\u2019s and Colitis Organization and European Society of Paediatric Gastroenterology, Hepatology and Nutrition. J Pediatr Gastroenterol Nutr. 2018;67(2):257\u201391.","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"2","key":"702_CR2","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1093\/ecco-jcc\/jjaa161","volume":"15","author":"PF van Rheenen","year":"2020","unstructured":"van Rheenen PF, et al. The medical management of paediatric Crohn\u2019s disease: an ECCO-ESPGHAN guideline update. J Crohns Colitis. 2020;15(2):171\u201394.","journal-title":"J Crohns Colitis"},{"key":"702_CR3","unstructured":"An overview of Stelara and why it is authorised in the EU. https:\/\/www.ema.europa.eu\/en\/documents\/overview\/stelara-epar-medicine-overview_en.pdf. An overview of Stelara and why it is authorised in the EU. https:\/\/www.ema.europa.eu\/en\/documents\/overview\/entyvio-epar-summary-public_en.pdf. Accessed 22 May 2025."},{"key":"702_CR4","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.896550","volume":"13","author":"XC Cai","year":"2022","unstructured":"Cai XC, et al. Efficacy and safety of biological agents for the treatment of pediatric patients with psoriasis: a Bayesian analysis of six high-quality randomized controlled trials. Front Immunol. 2022;13: 896550.","journal-title":"Front Immunol"},{"key":"702_CR5","unstructured":"European Commission approves STELARA\u00ae (ustekinumab) for the treatment of moderately to severely active Crohn\u2019s disease in paediatric patients. https:\/\/innovativemedicine.jnj.com\/emea\/european-commission-approves-stelara-ustekinumab-for-the-treatment-of-moderately-to-severely-active-crohns-disease-in-paediatric-patients. Accessed 22 May 2025."},{"issue":"4","key":"702_CR6","first-page":"634","volume":"10","author":"M Classen","year":"2023","unstructured":"Classen M, Hoerning A. Current role of monoclonal antibody therapy in pediatric IBD: a special focus on therapeutic drug monitoring and treat-to-target strategies. Children (Basel). 2023;10(4):634.","journal-title":"Children (Basel)"},{"issue":"9","key":"702_CR7","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1093\/ecco-jcc\/jjac055","volume":"16","author":"MT Dolinger","year":"2022","unstructured":"Dolinger MT, et al. Outcomes of children with inflammatory bowel disease who develop anti-tumour necrosis factor-induced skin reactions. J Crohns Colitis. 2022;16(9):1420\u20137.","journal-title":"J Crohns Colitis"},{"issue":"5","key":"702_CR8","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1007\/s40272-023-00586-7","volume":"25","author":"S Fang","year":"2023","unstructured":"Fang S, et al. Effectiveness and safety of ustekinumab for pediatric inflammatory bowel disease: a systematic review. Paediatr Drugs. 2023;25(5):499\u2013513.","journal-title":"Paediatr Drugs"},{"issue":"5","key":"702_CR9","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1038\/s41390-023-02913-7","volume":"96","author":"O Hradsky","year":"2024","unstructured":"Hradsky O, et al. Sustainability of biologic treatment in paediatric patients with Crohn\u2019s disease: population-based registry analysis. Pediatr Res. 2024;96(5):1283\u201391.","journal-title":"Pediatr Res"},{"issue":"8","key":"702_CR10","doi-asserted-by":"publisher","first-page":"3253","DOI":"10.1007\/s00431-024-05588-2","volume":"183","author":"G Pujol-Muncunill","year":"2024","unstructured":"Pujol-Muncunill G, et al. STEP-CD study: ustekinumab use in paediatric Crohn\u2019s disease\u2014a multicentre retrospective study from paediatric IBD Porto Group of ESPGHAN. Eur J Pediatr. 2024;183(8):3253\u201362.","journal-title":"Eur J Pediatr"},{"issue":"6","key":"702_CR11","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1097\/MPG.0000000000003608","volume":"75","author":"A Yerushalmy-Feler","year":"2022","unstructured":"Yerushalmy-Feler A, et al. Safety and potential efficacy of escalating dose of ustekinumab in pediatric Crohn disease (the speed-up study): a multicenter study from the pediatric IBD Porto Group of ESPGHAN. J Pediatr Gastroenterol Nutr. 2022;75(6):717\u201323.","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"5","key":"702_CR12","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1111\/apt.17092","volume":"56","author":"O Atia","year":"2022","unstructured":"Atia O, et al. Children included in randomised controlled trials of biologics in inflammatory bowel diseases do not represent the real-world patient mix. Aliment Pharmacol Ther. 2022;56(5):794\u2013801.","journal-title":"Aliment Pharmacol Ther"},{"issue":"9","key":"702_CR13","doi-asserted-by":"publisher","first-page":"3029","DOI":"10.1007\/s00431-021-04063-6","volume":"180","author":"R Garcia-Romero","year":"2021","unstructured":"Garcia-Romero R, et al. Safety and effectiveness of vedolizumab in paediatric patients with inflammatory bowel disease: an observational multicentre Spanish study. Eur J Pediatr. 2021;180(9):3029\u201338.","journal-title":"Eur J Pediatr"},{"issue":"37","key":"702_CR14","doi-asserted-by":"publisher","DOI":"10.3346\/jkms.2022.37.e282","volume":"37","author":"S Choi","year":"2022","unstructured":"Choi S, et al. Vedolizumab is safe and efficacious for the treatment of pediatric-onset inflammatory bowel disease patients who fail a primary biologic agent. J Korean Med Sci. 2022;37(37): e282.","journal-title":"J Korean Med Sci"},{"issue":"7","key":"702_CR15","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1016\/j.clinthera.2022.06.004","volume":"44","author":"T Kakiuchi","year":"2022","unstructured":"Kakiuchi T, Yoshiura M. Vedolizumab as the first-line of biologicals for pediatric patients with ulcerative colitis. Clin Ther. 2022;44(7):1028\u201332.","journal-title":"Clin Ther"},{"issue":"1","key":"702_CR16","doi-asserted-by":"publisher","DOI":"10.1097\/PG9.0000000000000276","volume":"4","author":"H Patel","year":"2023","unstructured":"Patel H, Karam L, Kellermayer R. A single-center study of long-term effectiveness of vedolizumab in anti-tnf refractory pediatric inflammatory bowel disease. JPGN Rep. 2023;4(1): e276.","journal-title":"JPGN Rep"},{"issue":"1","key":"702_CR17","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1186\/s12876-018-0868-x","volume":"18","author":"AM Schneider","year":"2018","unstructured":"Schneider AM, et al. Vedolizumab use after failure of TNF-alpha antagonists in children and adolescents with inflammatory bowel disease. BMC Gastroenterol. 2018;18(1):140.","journal-title":"BMC Gastroenterol"},{"issue":"7","key":"702_CR18","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1111\/jgh.16246","volume":"38","author":"K Yokoyama","year":"2023","unstructured":"Yokoyama K, et al. Safety and efficacy of vedolizumab in pediatric patients with ulcerative colitis: multicenter study in Japan. J Gastroenterol Hepatol. 2023;38(7):1107\u201315.","journal-title":"J Gastroenterol Hepatol"},{"issue":"12","key":"702_CR19","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.1007\/s00431-020-03750-0","volume":"179","author":"MME Jongsma","year":"2020","unstructured":"Jongsma MME, et al. Infliximab in young paediatric IBD patients: it is all about the dosing. Eur J Pediatr. 2020;179(12):1935\u201344.","journal-title":"Eur J Pediatr"},{"key":"702_CR20","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.coph.2020.09.002","volume":"55","author":"D Alsoud","year":"2020","unstructured":"Alsoud D, Vermeire S, Verstockt B. Monitoring vedolizumab and ustekinumab drug levels in patients with inflammatory bowel disease: hype or hope? Curr Opin Pharmacol. 2020;55:17\u201330.","journal-title":"Curr Opin Pharmacol"},{"issue":"5","key":"702_CR21","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1007\/s11894-018-0623-z","volume":"20","author":"N Carman","year":"2018","unstructured":"Carman N, Mack DR, Benchimol EI. Therapeutic drug monitoring in pediatric inflammatory bowel disease. Curr Gastroenterol Rep. 2018;20(5):18.","journal-title":"Curr Gastroenterol Rep"},{"issue":"2","key":"702_CR22","doi-asserted-by":"publisher","first-page":"250","DOI":"10.3390\/medicina60020250","volume":"60","author":"K Dutt","year":"2024","unstructured":"Dutt K, Vasudevan A. Therapeutic drug monitoring for biologic and small-molecule therapies for inflammatory bowel disease. Medicina (Kaunas). 2024;60(2):250.","journal-title":"Medicina (Kaunas)"},{"issue":"5","key":"702_CR23","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1136\/flgastro-2021-102032","volume":"13","author":"IO Nassar","year":"2022","unstructured":"Nassar IO, et al. Proposed pathway for therapeutic drug monitoring and dose escalation of vedolizumab. Frontline Gastroenterol. 2022;13(5):430\u20135.","journal-title":"Frontline Gastroenterol"},{"issue":"1","key":"702_CR24","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s12916-019-1323-8","volume":"17","author":"L Pouillon","year":"2019","unstructured":"Pouillon L, Vermeire S, Bossuyt P. Vedolizumab trough level monitoring in inflammatory bowel disease: a state-of-the-art overview. BMC Med. 2019;17(1):89.","journal-title":"BMC Med"},{"issue":"4","key":"702_CR25","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1093\/ibd\/izad065","volume":"30","author":"A Vasudevan","year":"2024","unstructured":"Vasudevan A, et al. Systematic review and meta-analysis: the association between serum ustekinumab trough concentrations and treatment response in inflammatory bowel disease. Inflamm Bowel Dis. 2024;30(4):660\u201370.","journal-title":"Inflamm Bowel Dis"},{"issue":"22","key":"702_CR26","doi-asserted-by":"publisher","first-page":"2902","DOI":"10.3748\/wjg.v30.i22.2902","volume":"30","author":"N Vootukuru","year":"2024","unstructured":"Vootukuru N, Vasudevan A. Approach to loss of response to advanced therapies in inflammatory bowel disease. World J Gastroenterol. 2024;30(22):2902\u201319.","journal-title":"World J Gastroenterol"},{"key":"702_CR27","doi-asserted-by":"publisher","first-page":"175628481877278","DOI":"10.1177\/1756284818772786","volume":"11","author":"MG Ward","year":"2018","unstructured":"Ward MG, Sparrow MP, Roblin X. Therapeutic drug monitoring of vedolizumab in inflammatory bowel disease: current data and future directions. Ther Adv Gastroenterol. 2018;11:1756284818772786.","journal-title":"Ther Adv Gastroenterol"},{"issue":"7","key":"702_CR28","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1111\/apt.14548","volume":"47","author":"W Yacoub","year":"2018","unstructured":"Yacoub W, et al. Early vedolizumab trough levels predict mucosal healing in inflammatory bowel disease: a multicentre prospective observational study. Aliment Pharmacol Ther. 2018;47(7):906\u201312.","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"702_CR29","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1093\/ecco-jcc\/jjab178","volume":"16","author":"T Raine","year":"2022","unstructured":"Raine T, et al. ECCO guidelines on therapeutics in ulcerative colitis: medical treatment. J Crohns Colitis. 2022;16(1):2\u201317.","journal-title":"J Crohns Colitis"},{"issue":"1","key":"702_CR30","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1093\/ecco-jcc\/jjz180","volume":"14","author":"J Torres","year":"2020","unstructured":"Torres J, et al. ECCO guidelines on therapeutics in Crohn\u2019s disease: medical treatment. J Crohns Colitis. 2020;14(1):4\u201322.","journal-title":"J Crohns Colitis"},{"issue":"5","key":"702_CR31","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1053\/j.gastro.2020.12.031","volume":"160","author":"D Turner","year":"2021","unstructured":"Turner D, et al. STRIDE-II: an update on the selecting therapeutic targets in inflammatory bowel disease (STRIDE) initiative of the International Organization for the Study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD. Gastroenterology. 2021;160(5):1570\u201383.","journal-title":"Gastroenterology"},{"issue":"6","key":"702_CR32","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1097\/MPG.0000000000000239","volume":"58","author":"A Levine","year":"2014","unstructured":"Levine A, et al. ESPGHAN revised porto criteria for the diagnosis of inflammatory bowel disease in children and adolescents. J Pediatr Gastroenterol Nutr. 2014;58(6):795\u2013806.","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"702_CR33","doi-asserted-by":"publisher","first-page":"1180750","DOI":"10.3389\/fphar.2023.1180750","volume":"14","author":"M Bouhuys","year":"2023","unstructured":"Bouhuys M, Mian P, van Rheenen PF. Ustekinumab trough levels in children with Crohn\u2019s disease refractory to anti-tumor necrosis factor agents: a prospective case series of off-label use. Front Pharmacol. 2023;14:1180750.","journal-title":"Front Pharmacol"},{"issue":"1","key":"702_CR34","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1097\/MPG.0000000000002362","volume":"69","author":"JR Dayan","year":"2019","unstructured":"Dayan JR, et al. Real world experience with ustekinumab in children and young adults at a tertiary care pediatric inflammatory bowel disease center. J Pediatr Gastroenterol Nutr. 2019;69(1):61\u20137.","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"12","key":"702_CR35","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.1111\/apt.16388","volume":"53","author":"J Dhaliwal","year":"2021","unstructured":"Dhaliwal J, et al. One-year outcomes with ustekinumab therapy in infliximab-refractory paediatric ulcerative colitis: a multicentre prospective study. Aliment Pharmacol Ther. 2021;53(12):1300\u20138.","journal-title":"Aliment Pharmacol Ther"},{"key":"702_CR36","doi-asserted-by":"publisher","first-page":"316","DOI":"10.12688\/f1000research.22673.1","volume":"9","author":"P Do","year":"2020","unstructured":"Do P, et al. Augmented ustekinumab dosing is needed to achieve clinical response in patients with anti-TNF refractory pediatric Crohn\u2019s disease: a retrospective chart review. F1000Res. 2020;9:316.","journal-title":"F1000Res"},{"issue":"5","key":"702_CR37","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1097\/MPG.0000000000003230","volume":"73","author":"FS Kim","year":"2021","unstructured":"Kim FS, et al. Experience using ustekinumab in pediatric patients with medically refractory Crohn disease. J Pediatr Gastroenterol Nutr. 2021;73(5):610\u20134.","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"11","key":"702_CR38","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.1093\/ecco-jcc\/jjab089","volume":"15","author":"JR Rosh","year":"2021","unstructured":"Rosh JR, et al. Ustekinumab in paediatric patients with moderately to severely active Crohn\u2019s disease: pharmacokinetics, safety, and efficacy results from UniStar, a phase 1 study. J Crohns Colitis. 2021;15(11):1931\u201342.","journal-title":"J Crohns Colitis"},{"issue":"2","key":"702_CR39","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1002\/jpn3.12252","volume":"79","author":"D Turner","year":"2024","unstructured":"Turner D, et al. Ustekinumab in paediatric patients with moderately to severely active Crohn\u2019s disease: UniStar study long-term extension results. J Pediatr Gastroenterol Nutr. 2024;79(2):315\u201324.","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"4","key":"702_CR40","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1111\/bjd.19018","volume":"183","author":"S Philipp","year":"2020","unstructured":"Philipp S, et al. Ustekinumab for the treatment of moderate-to-severe plaque psoriasis in paediatric patients (\u2265 6 to < 12 years of age): efficacy, safety, pharmacokinetic and biomarker results from the open-label CADMUS Jr study. Br J Dermatol. 2020;183(4):664\u201372.","journal-title":"Br J Dermatol"},{"issue":"5","key":"702_CR41","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1007\/s40272-024-00631-z","volume":"26","author":"S Cohen","year":"2024","unstructured":"Cohen S, et al. Effectiveness and safety of ustekinumab in pediatric ulcerative colitis: a multi-center retrospective study from the pediatric IBD Porto Group of ESPGHAN. Paediatr Drugs. 2024;26(5):609\u201317.","journal-title":"Paediatr Drugs"},{"issue":"2","key":"702_CR42","doi-asserted-by":"publisher","DOI":"10.1097\/PG9.0000000000000205","volume":"3","author":"J Sunny","year":"2022","unstructured":"Sunny J, et al. Hypersensitivity Reaction to ustekinumab in pediatric and young adult inflammatory bowel disease patients: a case series. JPGN Rep. 2022;3(2): e205.","journal-title":"JPGN Rep"},{"issue":"8","key":"702_CR43","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1093\/ecco-jcc\/jjac036","volume":"16","author":"JS Hyams","year":"2022","unstructured":"Hyams JS, et al. Pharmacokinetics, safety and efficacy of intravenous vedolizumab in paediatric patients with ulcerative colitis or Crohn\u2019s disease: results from the phase 2 HUBBLE study. J Crohns Colitis. 2022;16(8):1243\u201354.","journal-title":"J Crohns Colitis"},{"issue":"4","key":"702_CR44","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1097\/MPG.0000000000002833","volume":"71","author":"MA Aardoom","year":"2020","unstructured":"Aardoom MA, et al. Vedolizumab trough levels in children with anti-tumor necrosis factor refractory inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2020;71(4):501\u20137.","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"5","key":"702_CR45","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1111\/apt.17277","volume":"57","author":"RJ Colman","year":"2023","unstructured":"Colman RJ, et al. Real world population pharmacokinetic study in children and young adults with inflammatory bowel disease discovers novel blood and stool microbial predictors of vedolizumab clearance. Aliment Pharmacol Ther. 2023;57(5):524\u201339.","journal-title":"Aliment Pharmacol Ther"},{"issue":"4","key":"702_CR46","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1002\/jpn3.12132","volume":"78","author":"P Rowland","year":"2024","unstructured":"Rowland P, et al. Proactive therapeutic drug monitoring and vedolizumab dose optimization in children with inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2024;78(4):853\u201361.","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"8","key":"702_CR47","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1093\/ecco-jcc\/jjz041","volume":"13","author":"RC Ungaro","year":"2019","unstructured":"Ungaro RC, et al. Higher trough vedolizumab concentrations during maintenance therapy are associated with corticosteroid-free remission in inflammatory bowel disease. J Crohns Colitis. 2019;13(8):963\u20139.","journal-title":"J Crohns Colitis"},{"issue":"1","key":"702_CR48","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1007\/s00431-023-05255-y","volume":"183","author":"M Hemming-Harlo","year":"2024","unstructured":"Hemming-Harlo M, et al. Drug levels of VEDOLIZUMAB in patients with pediatric-onset inflammatory bowel disease in a real-life setting. Eur J Pediatr. 2024;183(1):313\u201322.","journal-title":"Eur J Pediatr"},{"issue":"1","key":"702_CR49","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S2468-1253(22)00307-7","volume":"8","author":"O Atia","year":"2023","unstructured":"Atia O, et al. Outcomes, dosing, and predictors of vedolizumab treatment in children with inflammatory bowel disease (VEDOKIDS): a prospective, multicentre cohort study. Lancet Gastroenterol Hepatol. 2023;8(1):31\u201342.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"3","key":"702_CR50","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/S2468-1253(24)00319-4","volume":"10","author":"O Atia","year":"2025","unstructured":"Atia O, et al. Maintenance treatment with vedolizumab in paediatric inflammatory bowel disease (VEDOKIDS): 54-week outcomes of a multicentre, prospective, cohort study. Lancet Gastroenterol Hepatol. 2025;10(3):234\u201347.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"6","key":"702_CR51","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1111\/apt.18484","volume":"61","author":"R Stein","year":"2025","unstructured":"Stein R, et al. Baseline drug clearance predicts outcomes in children with inflammatory bowel disease treated with vedolizumab: results from the vedokids prospective multicentre study. Aliment Pharmacol Ther. 2025;61(6):1000\u201310.","journal-title":"Aliment Pharmacol Ther"},{"issue":"2","key":"702_CR52","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1002\/ygh2.444","volume":"3","author":"A Outtier","year":"2021","unstructured":"Outtier A, et al. Effect of vedolizumab dose intensification on serum drug concentrations and regain of response in inflammatory bowel disease patients with secondary loss of response. GastroHep. 2021;3(2):63\u201371.","journal-title":"GastroHep"},{"issue":"5","key":"702_CR53","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1016\/j.cgh.2017.11.050","volume":"16","author":"B Ungar","year":"2018","unstructured":"Ungar B, et al. Association of vedolizumab level, anti-drug antibodies, and alpha4beta7 occupancy with response in patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol. 2018;16(5):697-705e7.","journal-title":"Clin Gastroenterol Hepatol"}],"container-title":["Pediatric Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40272-025-00702-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40272-025-00702-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40272-025-00702-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T00:33:50Z","timestamp":1757205230000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40272-025-00702-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,26]]},"references-count":53,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["702"],"URL":"https:\/\/doi.org\/10.1007\/s40272-025-00702-9","relation":{},"ISSN":["1174-5878","1179-2019"],"issn-type":[{"type":"print","value":"1174-5878"},{"type":"electronic","value":"1179-2019"}],"subject":[],"published":{"date-parts":[[2025,6,26]]},"assertion":[{"value":"23 May 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Open access publishing supported by the institutions participating in the CzechELib Transformative Agreement. This work was supported by the Ministry of Health, Czech Republic, for conceptual development of research organizations [00064203\/6001, University Hospital Motol, Prague, Czech Republic], and GAUK 227023.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"J.B.: lectures\/congress fees\/consultancy (outside submitted work)\u2014MSD, AbbVie, Nutricia, Nestl\u00e9, Sanofi, Pfizer and Vitabalans; K.Z: lectures\/congress fees\/consultancy (outside submitted work)\u2014Nestl\u00e9 and ProMed; M.D.: congress fees (outside submitted work)\u2014Nutricia; D.K.: lectures\/workshop fee (outside submitted work)\u2014Takeda and Vitabalans; M.K.: congress fees (outside submitted work)\u2014Fresenius and Accord; T.L.: lectures\/congress fees\/consultancy (outside submitted work)\u2014Accord, Nutricia, Biocodex and Ferring; K.M.: lectures\/consultancy (outside submitted work)\u2014Eli-Lilly and Takeda; E.V.: congress fees (outside submitted work)\u2014Ewopharma; O.H.: lectures\/congress fees\/consultancy (outside submitted work)\u2014MSD, AbbVie, Takeda, Sandoz, Lilly, Nutricia and Pfizer; I.C., J.Du., and J.Do. report no conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interests"}},{"value":"Full data available on request.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"The study was approved by the local ethics committee (EK, 662\/23).","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Parents of all patients provided written informed consent before inclusion in the study and publication of the data.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Participation and Publication of Data"}},{"value":"Full statistical code available on request.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"J.B. (guarantor of the article)\u2014study design, literature search, review of literature, data analysis, drafting of the manuscript and project supervision; O.H.\u2014study design, acquisition of data, statistical analysis and revision of manuscript draft; K.Z., I.C., M.D., D.K., M.K., T.L., K.M., E.V., J.Du., J.Do.\u2014study design, acquisition of data and revision of manuscript draft. All authors read and approved the final version of the manuscript.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}